BI's Giotrif set for EU lung cancer approval
This article was originally published in Scrip
Executive Summary
The CHMP has granted a positive opinion on Boehringer Ingelheim's targeted anticancer Giotrif (afatinib) for use in non-small cell lung cancer, just weeks after the product received its first approval from the US FDA.